Bausch + Lomb Corporation (BLCO)

Over the past six months, Bausch + Lomb's stock has yielded a 6.0% return, with a 52-week trading range between $10.45 and $18.92. Key events include the Q4 and Full-Year 2025 earnings announcement, which showed better-than-expected revenue but lower-than-expected EPS, along with 2026 revenue and adjusted EBITDA guidance. Positive ELIOS™ System trial data for glaucoma treatment was announced. A voluntary recall of enVista intraocular lenses due to toxic anterior segment syndrome (TASS) led to a securities fraud investigation. The CEO and Chairman, Brent L. Saunders, reported buying 14,700 common shares in an open-market transaction.

Demand seasonality for Bausch + Lomb's products and services is expected to be more pronounced due to its dry eye franchise, with the first quarter (Q1) typically being the lowest and the fourth quarter (Q4) being the highest.

Bausch + Lomb Corporation is a global eye health company operating in the Health Technology sector, specifically in the Medical Specialties and Ophthalmic Goods Manufacturing industries. The company offers a comprehensive portfolio of over 400 products across three primary segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment includes contact lenses and ocular health products. The Ophthalmic Pharmaceuticals segment provides prescription eye care products for conditions like glaucoma, eye infections, and dry eyes. The Surgical segment offers medical device equipment and technologies for various surgeries.

Headquartered in Vaughan, Ontario, Canada, Bausch + Lomb has a significant global presence with approximately 13,500 employees. The company operates in nearly 100 countries, with 24 manufacturing facilities located in 10 countries, spanning North America, South America, Europe, and Asia.

Bausch + Lomb has a long-standing reputation for its trusted brands. However, in the past year, its brand reputation has been significantly impacted by the voluntary recall of its enVista intraocular lenses due to reports of toxic anterior segment syndrome (TASS), leading to a securities fraud investigation. Positive developments include findings highlighting the role of LUMIFY® eye drops and positive data on its ELIOS™ System for glaucoma treatment.

Bausch Health Companies Inc. is the largest individual shareholder, owning 87.62% of the company. Major institutional owners include Icahn Carl C, Deutsche Bank Ag and others. Institutional investors hold approximately 11.19% of the stock, while insiders hold about 88.61%.